CU Anschutz Develops Trauma Recovery Blood Test
Analysis based on 7 articles · First reported Feb 11, 2026 · Last updated Feb 17, 2026
This medical breakthrough is expected to significantly impact the healthcare and biotechnology sectors by enabling personalized trauma care and potentially leading to the development of new therapeutics. Companies involved in medical diagnostics and emergency medicine may see increased interest and investment.
Researchers at the University of Colorado Anschutz have developed a novel blood test that can predict trauma patient recovery and the onset of complications, such as organ failure and mortality, with 92% accuracy, days in advance. Published in Science Translational Medicine, this study utilized 'omics' markers (proteomics and metabolomics) from over 1,300 trauma patients to map molecular endotypes and trajectories. This breakthrough, led by Mitchell Cohen, Kirk Hansen, and Angelo D Alessandro, allows for personalized treatment tailored to individual biological responses, moving beyond traditional injury-based assessments. The technology is being adapted for rapid, point-of-care testing in emergency and military settings, with the United States===United States Department of Defense funding the CRYO FIRST trial, which will be directly influenced by this research.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard